Align Technology Stock Forecast, Price & News

Align Technology (NASDAQ:ALGN) Frequently Asked Questions

Is Align Technology a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Align Technology in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Align Technology stock.
View analyst ratings for Align Technology or view top-rated stocks.

How has Align Technology's stock been impacted by COVID-19?

Align Technology's stock was trading at $202.18 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALGN stock has increased by 197.9% and is now trading at $602.29.
View which stocks have been most impacted by COVID-19.

Are investors shorting Align Technology?

Align Technology saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,550,000 shares, an increase of 24.0% from the October 31st total of 1,250,000 shares. Based on an average daily trading volume, of 590,400 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.1% of the shares of the company are short sold.
View Align Technology's Short Interest.

When is Align Technology's next earnings date?

Align Technology is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for Align Technology.

How were Align Technology's earnings last quarter?

Align Technology, Inc. (NASDAQ:ALGN) issued its quarterly earnings data on Tuesday, October, 26th. The medical equipment provider reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.60 by $0.27. The medical equipment provider earned $1.02 billion during the quarter, compared to analyst estimates of $977.81 million. Align Technology had a trailing twelve-month return on equity of 21.88% and a net margin of 19.70%. The firm's revenue was up 38.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.76 earnings per share.
View Align Technology's earnings history.

What guidance has Align Technology issued on next quarter's earnings?

Align Technology issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.90 billion-$3.95 billion, compared to the consensus revenue estimate of $3.94 billion.

What price target have analysts set for ALGN?

13 equities research analysts have issued twelve-month price objectives for Align Technology's shares. Their forecasts range from $555.00 to $825.00. On average, they anticipate Align Technology's share price to reach $735.83 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Align Technology or view top-rated stocks among Wall Street analysts.

Who are Align Technology's key executives?

Align Technology's management team includes the following people:

• Joseph M. Hogan, President, Chief Executive Officer & Director
• Emory M. Wright, Senior Vice President-Global Operations (LinkedIn Profile)
• John F. Morici, Chief Financial Officer & SVP-Global Finance (LinkedIn Profile)
• Zelko Relic, Chief Technology Officer & Senior Vice President
• Jennifer Olson, SVP & MD, Doctor-Directed Consumer Channel

What is Joe Hogan's approval rating as Align Technology's CEO?

346 employees have rated Align Technology CEO Joe Hogan on Glassdoor.com. Joe Hogan has an approval rating of 97% among Align Technology's employees. This puts Joe Hogan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Align Technology's key competitors?

Some companies that are related to Align Technology include West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Neogen (NEOG), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).
View all of ALGN's competitors.

What other stocks do shareholders of Align Technology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Align Technology investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), PayPal (PYPL), Micron Technology (MU), Adobe (ADBE), Visa (V), salesforce.com (CRM), Mastercard (MA) and Tesla (TSLA).

What is Align Technology's stock symbol?

Align Technology trades on the NASDAQ under the ticker symbol "ALGN."

Who are Align Technology's major shareholders?

Align Technology's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.00%), Edgewood Management LLC (5.68%), Sands Capital Management LLC (3.68%), Wellington Management Group LLP (2.72%), Janus Henderson Group PLC (2.66%) and Alliancebernstein L.P. (2.22%). Company insiders that own Align Technology stock include Andrea Lynn Saia, C Raymond Larkin Jr, C Raymond Larkin, Jr, Emory Wright, George J Morrow, John Morici, Joseph Lacob, Joseph M Hogan, Julie Ann Coletti, Julie Tay, Kevin C Burns, Robert E Fitzgerald, Simon Beard, Stuart A Hockridge, Susan E Siegel, Thomas M Prescott, Vamsi Mohan Raj Pudipeddi, Warren S Thaler, Yuval Shaked and Zelko Relic.
View institutional ownership trends for Align Technology.

Which major investors are selling Align Technology stock?

ALGN stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Invesco Ltd., Citigroup Inc., Polar Capital Holdings Plc, Morgan Stanley, Bank of New York Mellon Corp, Deutsche Bank AG, and Assenagon Asset Management S.A.. Company insiders that have sold Align Technology company stock in the last year include C Raymond Larkin Jr, C Raymond Larkin, Jr, Emory Wright, George J Morrow, John Morici, Julie Ann Coletti, Kevin C Burns, Stuart A Hockridge, Thomas M Prescott, and Warren S Thaler.
View insider buying and selling activity for Align Technology or view top insider-selling stocks.

Which major investors are buying Align Technology stock?

ALGN stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, Wellington Management Group LLP, Arrowstreet Capital Limited Partnership, Los Angeles Capital Management LLC, Alliancebernstein L.P., Nordea Investment Management AB, and Manning & Napier Group LLC.
View insider buying and selling activity for Align Technology or or view top insider-buying stocks.

How do I buy shares of Align Technology?

Shares of ALGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Align Technology's stock price today?

One share of ALGN stock can currently be purchased for approximately $602.29.

How much money does Align Technology make?

Align Technology has a market capitalization of $47.49 billion and generates $2.47 billion in revenue each year. The medical equipment provider earns $1.78 billion in net income (profit) each year or $9.30 on an earnings per share basis.

How many employees does Align Technology have?

Align Technology employs 18,070 workers across the globe.

When was Align Technology founded?

Align Technology was founded in 1997.

What is Align Technology's official website?

The official website for Align Technology is www.aligntech.com.

Where are Align Technology's headquarters?

Align Technology is headquartered at 2820 ORCHARD PARKWAY, SAN JOSE CA, 95134.

How can I contact Align Technology?

Align Technology's mailing address is 2820 ORCHARD PARKWAY, SAN JOSE CA, 95134. The medical equipment provider can be reached via phone at (408) 470-1000, via email at [email protected], or via fax at 408-470-1010.